Transcriptomic profiles
DISEASE, CLL, TRISOMY 12, DELETION
Pre-treatment RNAseq data from CD19-enriched peripheral blood samples, i.e. enriched for the CLL cell fraction, were available for 405 of the 432 randomized patients (203 Ven-Obi, 202 Clb-Obi). RNAseq data from CD19-enriched peripheral blood samples at first disease relapse were available for 29 of 52 relapsed patients in the Ven-Obi arm (Supplementary Table To obtain a global overview on gene expression variation in CLL within a representative, treatment-naïve patient cohort, unsupervised shared nearest neighbour (SNN) clustering was performed. Patient samples were clustered by presence of IGHV mutational status, trisomy 12 and deletion 13q (Fig. 